Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma

作     者：Swamy, Supritha G. Kameshwar, Vivek H. Shubha, Priya B. Looi, Chung Yeng Shanmugam, Muthu K. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, Nanjunda Swamy Bishayee, Anupam 

作者机构：JSS Sci & Technol Univ Dept Biotechnol JSS Tech Inst Campus Mysore 570006 Karnataka India Univ Mysore Dept Studies Chem Mysore 570006 Karnataka India Univ Malaya Dept Pharmacol Fac Med Kuala Lumpur 50603 Malaysia Natl Univ Singapore Yong Loo Lin Sch Med Dept Pharmacol Singapore 117597 Singapore Curtin Univ Curtin Hlth Innovat Res Inst Sch Biomed Sci Biosci Res Precinct Bentley WA 6009 Australia Larkin Hlth Sci Inst Dept Pharmaceut Sci Coll Pharm 18301 N Miami Ave Miami FL 33169 USA 

出 版 物：《TARGETED ONCOLOGY》 (靶向肿瘤学)

年 卷 期：2017年第12卷第1期

页      面：1-10页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：SERB Fast Track Research Grant [SB/FT/LS-297/2012] NUHS Bench-to-Bedside grant University Malaya [RP027C-14HTM] University Malaya High Impact research grant [H-20001-E00002] 

主　　题：Hepatocellular Cancer Signal Transduction Pathways protein tyrosine kinase inhibitor chronic liver disease Cancer of Liver sorafenib Side Effect Human-centered computing 

摘      要：Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.